Evaluating JWK008 for Mucopolysaccharidosis Type I

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is designed to assess the safety, tolerability, and initial efficacy of JWK008, a novel gene therapy, in patients with Mucopolysaccharidosis Type I (MPS I). The study employs a single-center, open-label, non-randomized, dose-escalation approach to evaluate the effects of a single intravenous infusion of JWK008. The therapy aims to address the limitations of current treatments by enabling the IDUA enzyme to cross the blood-brain barrier, potentially providing therapeutic benefits for both systemic and central nervous system symptoms of MPS I. Participants will be closely monitored for safety and efficacy outcomes throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age≥ 18 years old;
2. Diagnosis of MPS type I;
3. Be able to understand the purpose, content, and possible risks of this clinical study, voluntarily participate in and sign the informed consent form;
4. If the subject is female, her sexual partner must agree to use reliable contraception until 2 consecutive tests of vector sequence in the blood are negative; If the subject is male, the subject agrees to use reliable contraception until the semen sample is negative for 2 consecutive tests of the vector sequence.
5. Magnetic resonance imaging (MRI) of the liver mass read by the radiologist is negative.

Exclusion Criteria:

1. Known to be unresponsive to ERT; or those who have been treated with intrathecal or intravenous laronidase and have serious adverse reactions, such as significant infusion-related reactions (IARs) or anaphylactic shock.
2. Serum AAV5 neutralizing antibody titer is greater than 1:100.
3. Has contraindications for Corticosteroids.
4. Current treatment with systemic (intravenous or oral) immunomodulators or steroid use (topical treatments such as asthma or eczema are allowed).
5. Has contraindications for lumbar puncture.
6. When filtering, one of the following situations exists:

   1. Hepatitis B surface antigen (HBsAg) is positive, and the copy number of hepatitis B virus deoxyribonucleic acid (HBV-DNA) is\>the upper limit of normal value (ULN);
   2. Hepatitis C virus antibody (HCV-Ab) is positive, and the copy number of hepatitis C virus ribonucleic acid (HCV-RNA) is\>ULN;
   3. Receiving antiviral treatment for hepatitis B or C;
   4. The human immunodeficiency virus (HIV) test is positive and the CD4+T lymphocyte count is ≤ 200/mm3;
7. Abnormal laboratory values considered clinically significant (ALT and/or AST \>3× upper limit of normal (ULN), total bilirubin \> 1.5× ULN, serum creatinine \> 1.5× ULN, etc.).
8. Have a history of chronic infections or other chronic diseases that researchers believe pose an unacceptable risk;
9. Active severe infection or any other significant accompanying, uncontrolled medical condition(except for those caused by MPS I), including but not limited to kidney, liver, blood, gastrointestinal, endocrine, lung, nervous system, brain or mental illness, alcoholism, drug dependence, or any psychological disorder assessed by the researcher that may interfere with adherence to experimental protocol procedures or tolerance to JWK008 injection;
10. History of active malignancy within the past 5 years (non-melanotic skin cancer or carcinoma in situ of the cervix is allowed).
11. Circulating alpha-fetoprotein (AFP) is elevated or abnormal.
12. Previously received gene therapy or participated in interventional clinical studies within the past 12 weeks;
13. Pregnant or lactating females.
14. The researcher believes that the subject is not suitable to participate in any concurrent clinically significant major diseases or other situations in the study;
15. Unable or unwilling to comply with the visit and study evaluation schedule described in the clinical protocol.

Where it's running

• West China Hospital, Sichuan Universit
  Chengdu, Sichuan, China Recruiting

Study contacts

• Principal investigator: Xingchen Peng, Ph.D — West China Hospital
• Study coordinator: Xingchen Peng, Ph.D
• Email: pxx2014@163.com
• Phone: +8618980606753

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant Cryo-Thermal Ablation with Toripalimab and Chemo for Resectable NSCLC

  This study tests whether using Cryo-Thermal Ablation before chemo-immunotherapy helps people with resectable NSCLC see better outcomes.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan and 8 other locations · NCT07855965

• Tai Chi during radiotherapy for head and neck cancer fatigue

  This trial tests whether a 12-week Yang-style Tai Chi program added to usual care can reduce cancer-related fatigue in adults with head and neck cancer undergoing radiotherapy.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07809776

• Wireless home prehabilitation for older adults with NSCLC awaiting lung surgery

  This study tests whether a personalized home exercise program guided by wearable devices can improve lung function for older NSCLC patients preparing for curative lung surgery.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07809763

• First-line combo therapy with GnP, SHR-1701, and Apatinib for metastatic pancreatic cancer

  This trial tests whether adding SHR-1701 and Apatinib to standard GnP can safely and effectively treat previously untreated metastatic pancreatic cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07802184

• Early warning and stratified diagnosis of postoperative respiratory failure using ventilator waveform features

  This study tests whether patterns in ventilator waveforms can predict and categorize risk of breathing failure after surgery for adults on mechanical ventilation.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07799636

• JWK001 subretinal therapy for neovascular AMD

  This study tests a single subretinal dose of JWK001 at different levels in people with wet age-related macular degeneration who have previously responded to anti-VEGF treatment.

  Recruiting at 2 sites Phase 2 West China Hospital · Beijing, Beijing Municipality and 15 other locations · NCT07776522

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.